Menu Search
Equities

Biofrontera Inc

BFRI:NAQ

Biofrontera Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.28
  • Today's Change-0.01 / -0.78%
  • Shares traded431.24k
  • 1 Year change-85.19%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Biofrontera Inc had net income fall 3,045.47% from a loss of 640.00k to a larger loss of 20.13m despite revenues that grew 18.82% from 28.67m to 34.07m over the same period.
Gross margin47.75%
Net profit margin-38.33%
Operating margin-33.92%
Return on assets-46.20%
Return on equity-149.41%
Return on investment-113.24%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Biofrontera Inc fell by 15.87m. Cash Flow from Financing totalled 8.41m or 24.69% of revenues. In addition the company used 24.90m for operations while cash from investing totalled 619.00k.
Cash flow per share-4.47
Price/Cash flow per share--
Book value per share2.14
Tangible book value per share1.66
More ▼

Balance sheet in USDView more

Biofrontera Inc uses little debt in its capital structure as supported by a debt to capital ratio of 2.64%.
Current ratio1.89
Quick ratio1.46
Total debt/total equity0.0271
Total debt/total capital0.0264
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.